Improving durability of responses after CAR T therapy for myeloma
Official title: Improving response durability after CAR T cell therapy for multiple myeloma
Funded at University of Pennsylvania · NIH-11413794 · Data updated 2026-11-12
This grant explores new CAR T cell approaches to keep multiple myeloma patients in remission longer after initial treatment success.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | August 15, 2017 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $573,479 |
| NIH project number | 5P01CA214278-09 |
| Project ID | NIH-11413794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with multiple myeloma who have responded to initial CAR T therapy or are eligible for next-generation CAR T strategies using MIL-derived cells.
✕Less likely to help
Patients who do not have MM or are not candidates for CAR T therapy may not benefit from this approach.
What this research studies
In people with multiple myeloma, initial responses to CAR T therapy often fade over time. The project aims to test strategies that prevent late relapse by using marrow-infiltrating lymphocytes to manufacture anti-BCMA CAR T cells and by addressing bone marrow factors that drive relapse. Researchers will combine clinical testing with pre-clinical studies to understand why CAR T cells stop controlling the disease and how to sustain their activity. The work builds on prior findings about T-cell features, CAR T-cell persistence, and the bone marrow environment to design safer, longer-lasting therapies.
Why it matters
Potential benefit: If successful, the approach could extend the duration of remission and improve survival for patients with multiple myeloma.
How similar studies have gone: Previous CAR T strategies have shown high initial responses but relapse remains a challenge, and this project builds on that knowledge with a novel MIL-derived CAR T approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Milone, Michael C. — University of Pennsylvania
- Study coordinator: Milone, Michael C.
Related research
Other NIH-funded projects on the same topics.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
In Vivo Engineering of BCMA CAR T Cells for Multiple Myeloma
A new NIH grant aims to develop lipid nanoparticle systems that deliver BCMA CAR instructions directly to patients’ immune cells to treat multiple myeloma.
-
BCMA CAR-T therapy with opaganib for ultrahigh risk multiple myeloma
A first-in-human-style treatment using a patient’s own CAR-T cells plus a targeted drug to help people with very high-risk multiple myeloma live longer and better.
-
Make CAR T therapy last longer for multiple myeloma
This project tries CAR T cells made from bone marrow immune cells to help people with multiple myeloma stay in remission longer.
-
Integrative study of multiple myeloma genetics and disease biology
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.